#podcast Phil Johnston, President & CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, & other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, & determine dosage and form for therapies. #MedicalCannabisClinicalResearch #CannabisRescheduling PWJohnston.com EOCare.com https://lnkd.in/gJ227Ep3
Karen Jagoda’s Post
More Relevant Posts
-
Chief Operating Officer at OP Innovates and co-founder of the brands, Overcome and Hemp Mellow; Co-Founder of Anavii Market
Curious about the safety of delta8? Tune in to this podcast with neurologist and leading cannabis researcher Dr. Ethan Russo, MD. You’ll understand why there are concerns and why we must be careful! https://lnkd.in/gTdKRTiK
To view or add a comment, sign in
-
Many thanks to Susan Van Meter, President of the American Clinical Laboratory Association, for joining me on the latest episode of the Votes & Verdicts podcast. We discussed the Biden administration's lab developed test oversight proposal and congressional reimbursement reform efforts. Listen to the full episode to hear about ACLA's legislative and regulatory agenda. Apple -- https://lnkd.in/dtC2AxeV Spotify -- https://lnkd.in/edVjwJqy #bloombergintelligence #clinicallaboratory #healthcare #podcast #bloomberg
Votes & Verdicts on Apple Podcasts
podcasts.apple.com
To view or add a comment, sign in
-
In this episode from The Journal, Bradley Olson shares his inspiring 20-year weight-loss journey. The discussion sheds light on the complexities of weight loss medication, addressing the delicate balance between cost, culture, and health. Hearing firsthand stories like Bradley's is essential as we navigate the challenges of managing the costs of these medications within employer health plans, government initiatives, and pharmaceutical strategies. Listen to Bradley's journey here: https://lnkd.in/gbn4Pdwv
Trillion Dollar Shot, Episode 3: Brad - The Journal. - WSJ Podcasts
wsj.com
To view or add a comment, sign in
-
In the latest of the Drug and Therapeutics Bulletin's 60th anniversary podcasts, Barbara Mintzes (Associate Professor at the School of Pharmacy and Charles Perkins Centre at the University of Sydney and DTB Editorial Board member) talks about her interest in national medicines policies, the impact of pharmaceutical and medical device company payments to clinicians, medicalisation of normal life, medicine safety scandals and the impact on those who have been harmed by medicines with a particular focus on women's health. https://bit.ly/3KhGAna
DTB 60th anniversary podcast interview - Barbara Mintzes | DTB Podcast
dtbbmj.podbean.com
To view or add a comment, sign in
-
Watch as Altasciences’ panel of experts discuss the FDA’s recently published guidelines for early-phase clinical development of psychedelics and the assessment of abuse potential. Topics covered: • important FDA recommendations; • clinical methods to optimize early-phase clinical trials with psychedelics; • how to address the abuse potential evaluation requirement for psychedelic drugs; and • strategies to ensure study integrity. #Psychedelics #DrugDevelopment #FDA
Watch now!
altasciences.com
To view or add a comment, sign in
-
Bringing Psychedelic Therapies to Market https://lnkd.in/d5sy3AZN 👉🏻 In this episode of No Plan B, Jean Fallacara's presentation by Dr. We're Discussing - Psychedelic Therapies to Market - with Dr. Anish Tuteja and Zappy Zapolin. ☝🏻 Psycheceutical, bringing psychedelic therapies to market by developing unique delivery technologies • Why are we at a pivotal juncture for getting psychedelic therapies approved and available? • Why do psychoactive therapies pose a unique challenge in FDA approvals? • What are various means of delivering psychoactive therapies, pros and cons of each, etc. Zappy Zapolin Jean Fallacara Dr. Anish Tuteja #fda #Discuss #Psychedelic #Therapi #Market #Psycheceutical #technology #FDA
Bringing Psychedelic Therapies to Market │ No Plan B Podcast │ Ep 11
https://www.youtube.com/
To view or add a comment, sign in
-
The latest podcast discusses the impact of formulary exclusions on patient outcomes with special guest, Catherine, who suffered through this heinous scheme perpetuated by PBMs https://lnkd.in/gFdiHX89 watch video of the webinar https://lnkd.in/g8tacSEG Conner Mertens
S4, Ep 8- Beyond the Formulary: Uncovering the Hidden Impact of Drug Exclusions
omny.fm
To view or add a comment, sign in
-
Our CEO, David Kooi, joined the Grassroots Marketing podcast to discuss reshaping perceptions of cannabis and plant medicine. The episode explores the journey of normalizing cannabis, draws comparisons with psychedelics, and highlights Spark, our AI assistant for purposeful cannabis use. Thanks to CannabisRadio.com and Grassroots Marketing for having us! Listen here: https://spoti.fi/48Ykwbp #cannabisindustry #cannabispodcast
To view or add a comment, sign in
-
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Belharra CEO talks the ins and outs of building a biotech in a new podcast >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #biotech #productmarketing
Belharra CEO talks the ins and outs of building a biotech in a new podcast
https://endpts.com
To view or add a comment, sign in
-
There's no disease that stress does not make worse and no disease that stress does not cause and so it's really important that we figure out how to mitigate our stress by intentionally crafting safety for ourselves. Learn more in my latest podcast! https://lnkd.in/esn_YUwU
Natural Alternatives to Pharmaceuticals with Dr. Lindsey Elmore (Episode 176)
https://doctordoni.com
To view or add a comment, sign in